よむ、つかう、まなぶ。
【参考資料5】抗微生物薬適正使用の手引き 第三版 別冊 (45 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_45318.html |
| 出典情報 | 厚生科学審議会 感染症部会 薬剤耐性（AMR）に関する小委員会 抗微生物薬適正使用（AMS）等に関する作業部会（第6回 11／19）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
抗微生物薬適正使用の手引き
第三版
別冊
127. Durante-Mangoni E, Signoriello G, Andini R. et al. Colistin and rifampicin compared with
colistin alone for the treatment of serious infections due to extensively drug-resistant
Acinetobacter baumannii: a multicenter, randomized clinical trial. Clin Infect Dis. 2013
Aug;57(3):349-358.
128. Park HJ, Cho JH, Kim HJ, Han SH, Jeong SH, Byun MK. Colistin monotherapy versus
colistin/rifampicin combination therapy in pneumonia caused by colistin-resistant
Acinetobacter baumannii: A randomised controlled trial. J Glob Antimicrob Resist. 2019
Jun;17:66-71.
129. Kaye KS, Marchaim D, Thamlikitkul V, et al. Colistin Monotherapy versus Combination
Therapy for Carbapenem-Resistant Organisms. NEJM Evid 2023;2.
130. Aydemir H, Akduman D, Piskin N. et al. Colistin vs. the combination of colistin and rifampicin
for the treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated
pneumonia. Epidemiol Infect. 2013 Jun;141(6):1214-1222.
131. Sirijatuphat R, Thamlikitkul V. Preliminary study of colistin versus colistin plus fosfomycin for
treatment of carbapenem-resistant Acinetobacter baumannii infections. Antimicrob Agents
Chemother. 2014 Sep;58(9):5598-5601.
132. Perez F, Adachi J, Bonomo RA. Antibiotic-resistant gram-negative bacterial infections in
patients with cancer. Clin Infect Dis. 2014 Nov;59 Suppl 5:S335-9.
133. Kengkla K, Kongpakwattana K, Saokaew S, Apisarnthanarak A, Chaiyakunapruk N.
Comparative efficacy and safety of treatment options for MDR and XDR Acinetobacter
baumannii infections: a systematic review and network meta-analysis. J Antimicrob
Chemother. 2018 Jan;73(1):22-32.
134. Chen H, Liu Q, Chen Z, Li C. Efficacy of sulbactam for the treatment of Acinetobacter
baumannii complex infection: A systematic review and meta-analysis. J Infect Chemother.
2017 May;23(5):278-285.
135. Jaruratanasirikul S, Wongpoowarak W, Aeinlang N, Jullangkoon M. Pharmacodynamics
modeling to optimize dosage regimens of sulbactam. Antimicrob Agents Chemother. 2013
Jul;57(7):3441-3444.
136. Jaruratanasirikul S, Wongpoowarak W, Wattanavijitkul T. et al. Population Pharmacokinetics
and Pharmacodynamics Modeling To Optimize Dosage Regimens of Sulbactam in Critically
Ill Patients with Severe Sepsis Caused by Acinetobacter baumannii. Antimicrob Agents
Chemother. 2016 Nov;60(12):7236-7244.
137. Brooke JS. Stenotrophomonas maltophilia: an emerging global opportunistic pathogen. Clin
Microbiol Rev. 2012 Jan;25(1):2-41.
138. Brooke JS. Advances in the Microbiology of Stenotrophomonas maltophilia. Clin Microbiol
Rev. 2021 Jul;34(3):e0003019.
139. Safdar A, Rolston KV. Stenotrophomonas maltophilia: changing spectrum of a serious
bacterial pathogen in patients with cancer. Clin Infect Dis. 2007 Dec;45(12):1602-1609.
140. Kim SH, Cha MK, Kang CI. et al. Pathogenic significance of hemorrhagic pneumonia in
hematologic malignancy patients with Stenotrophomonas maltophilia bacteremia: clinical and
microbiological analysis. Eur J Clin Microbiol Infect Dis. 2019 Feb;38(2):285-295.
45
第三版
別冊
127. Durante-Mangoni E, Signoriello G, Andini R. et al. Colistin and rifampicin compared with
colistin alone for the treatment of serious infections due to extensively drug-resistant
Acinetobacter baumannii: a multicenter, randomized clinical trial. Clin Infect Dis. 2013
Aug;57(3):349-358.
128. Park HJ, Cho JH, Kim HJ, Han SH, Jeong SH, Byun MK. Colistin monotherapy versus
colistin/rifampicin combination therapy in pneumonia caused by colistin-resistant
Acinetobacter baumannii: A randomised controlled trial. J Glob Antimicrob Resist. 2019
Jun;17:66-71.
129. Kaye KS, Marchaim D, Thamlikitkul V, et al. Colistin Monotherapy versus Combination
Therapy for Carbapenem-Resistant Organisms. NEJM Evid 2023;2.
130. Aydemir H, Akduman D, Piskin N. et al. Colistin vs. the combination of colistin and rifampicin
for the treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated
pneumonia. Epidemiol Infect. 2013 Jun;141(6):1214-1222.
131. Sirijatuphat R, Thamlikitkul V. Preliminary study of colistin versus colistin plus fosfomycin for
treatment of carbapenem-resistant Acinetobacter baumannii infections. Antimicrob Agents
Chemother. 2014 Sep;58(9):5598-5601.
132. Perez F, Adachi J, Bonomo RA. Antibiotic-resistant gram-negative bacterial infections in
patients with cancer. Clin Infect Dis. 2014 Nov;59 Suppl 5:S335-9.
133. Kengkla K, Kongpakwattana K, Saokaew S, Apisarnthanarak A, Chaiyakunapruk N.
Comparative efficacy and safety of treatment options for MDR and XDR Acinetobacter
baumannii infections: a systematic review and network meta-analysis. J Antimicrob
Chemother. 2018 Jan;73(1):22-32.
134. Chen H, Liu Q, Chen Z, Li C. Efficacy of sulbactam for the treatment of Acinetobacter
baumannii complex infection: A systematic review and meta-analysis. J Infect Chemother.
2017 May;23(5):278-285.
135. Jaruratanasirikul S, Wongpoowarak W, Aeinlang N, Jullangkoon M. Pharmacodynamics
modeling to optimize dosage regimens of sulbactam. Antimicrob Agents Chemother. 2013
Jul;57(7):3441-3444.
136. Jaruratanasirikul S, Wongpoowarak W, Wattanavijitkul T. et al. Population Pharmacokinetics
and Pharmacodynamics Modeling To Optimize Dosage Regimens of Sulbactam in Critically
Ill Patients with Severe Sepsis Caused by Acinetobacter baumannii. Antimicrob Agents
Chemother. 2016 Nov;60(12):7236-7244.
137. Brooke JS. Stenotrophomonas maltophilia: an emerging global opportunistic pathogen. Clin
Microbiol Rev. 2012 Jan;25(1):2-41.
138. Brooke JS. Advances in the Microbiology of Stenotrophomonas maltophilia. Clin Microbiol
Rev. 2021 Jul;34(3):e0003019.
139. Safdar A, Rolston KV. Stenotrophomonas maltophilia: changing spectrum of a serious
bacterial pathogen in patients with cancer. Clin Infect Dis. 2007 Dec;45(12):1602-1609.
140. Kim SH, Cha MK, Kang CI. et al. Pathogenic significance of hemorrhagic pneumonia in
hematologic malignancy patients with Stenotrophomonas maltophilia bacteremia: clinical and
microbiological analysis. Eur J Clin Microbiol Infect Dis. 2019 Feb;38(2):285-295.
45